開発中のヒトパピローマウイルスマイナーキャプシドタンパク質L2市場2022年:治療領域、疾患、ステージ、MoA、RoA、分子タイプ、キープレーヤー

【英語タイトル】Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが出版した調査資料(GMDHC22036TDB)・商品コード:GMDHC22036TDB
・発行会社(調査会社):Global Markets Direct
・発行日:2022年3月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD10,500 ⇒換算¥1,554,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本調査レポートでは、開発中のヒトパピローマウイルスマイナーキャプシドタンパク質L2市場について調査・分析し、ヒトパピローマウイルスマイナーキャプシドタンパク質L2概要、治療薬開発、開発段階別の開発中製品、治療領域別の開発中製品、疾患別の開発中製品、企業別の開発中製品、大学/機関別の開発中製品、治療薬分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・ヒトパピローマウイルスマイナーキャプシドタンパク質L2-概要
・ヒトパピローマウイルスマイナーキャプシドタンパク質L2-治療薬開発
・開発段階別の開発中製品
・治療領域別の開発中製品
・疾患別の開発中製品
・企業別の開発中製品
・大学/機関別の開発中製品
・ヒトパピローマウイルスマイナーキャプシドタンパク質L2-治療薬分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・ヒトパピローマウイルスマイナーキャプシドタンパク質L2-治療薬開発に携わる企業

Human Papillomavirus Minor Capsid Protein L2 (L2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Human Papillomavirus Minor Capsid Protein L2 (L2) – L2 is a minor capsid component and lacks the capacity to form VLPs. This protein plays a role in capsid stabilization through interaction with the major capsid protein L1. It also plays a role through its interaction with host dyne in in the intracellular microtubule-dependent transport of viral capsid toward the nucleus. It mediates the viral genome import into the nucleus through binding to host importins.

Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Women’s Health which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Intraepithelial Neoplasia (CIN), Human Papillomavirus Infections, Anal Cancer, Cervical Cancer and Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

The latest report Human Papillomavirus Minor Capsid Protein L2 – Drugs In Development, 2022, outlays comprehensive information on the Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Minor Capsid Protein L2 (L2)
- The report reviews Human Papillomavirus Minor Capsid Protein L2 (L2)) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human Papillomavirus Minor Capsid Protein L2 (L2) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human Papillomavirus Minor Capsid Protein L2 (L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Minor Capsid Protein L2 (L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

❖ レポートの目次 ❖

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Human Papillomavirus Minor Capsid Protein L2 (L2) – Overview
Human Papillomavirus Minor Capsid Protein L2 (L2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human Papillomavirus Minor Capsid Protein L2 (L2) – Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Human Papillomavirus Minor Capsid Protein L2 (L2) – Companies Involved in Therapeutics Development
2A Pharma AB
Papivax LLC
Pathovax LLC
Human Papillomavirus Minor Capsid Protein L2 (L2) – Drug Profiles
2AP-01 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PANHPVAX – Drug Profile
Product Description
Mechanism Of Action
History of Events
PVX-01 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PVX-2 – Drug Profile
Product Description
Mechanism Of Action
History of Events
RGVax – Drug Profile
Product Description
Mechanism Of Action
History of Events
TA-CIN – Drug Profile
Product Description
Mechanism Of Action
History of Events
Human Papillomavirus Minor Capsid Protein L2 (L2) – Dormant Products
Human Papillomavirus Minor Capsid Protein L2 (L2) – Discontinued Products
Human Papillomavirus Minor Capsid Protein L2 (L2) – Product Development Milestones
Featured News & Press Releases
Dec 01, 2021: Jeanette presents E-poster at IPVC 2021
Nov 25, 2019: 2A Pharma announces the completion of dosing for 2AP01 vaccine
Mar 02, 2019: 2A Pharma initiates phase 1 clinical trial of HPV vaccine candidate
Dec 14, 2018: 2A Pharma receives approval for phase 1 study of 2AP-01
Apr 17, 2018: As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed
Oct 27, 2016: PathoVax Wins $500,000 in 43North Contest
Oct 30, 2014: National Cancer Institute supports next-generation Austrian HPV vaccine
Sep 10, 2013: New, Even More Effective HPV Vaccine In Sight
Apr 10, 2012: Medigene Presents Preclinical AAVLP Data At World Vaccine Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 2A Pharma AB, 2022
Pipeline by Papivax LLC, 2022
Pipeline by Pathovax LLC, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Molecule Types, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

★調査レポート[開発中のヒトパピローマウイルスマイナーキャプシドタンパク質L2市場2022年:治療領域、疾患、ステージ、MoA、RoA、分子タイプ、キープレーヤー] (コード:GMDHC22036TDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[開発中のヒトパピローマウイルスマイナーキャプシドタンパク質L2市場2022年:治療領域、疾患、ステージ、MoA、RoA、分子タイプ、キープレーヤー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆